Skip to main content
ARECOR THERAPEUTICS PLC logo

ARECOR THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AREC ISIN · GB00BMWLM973 LEI · 98450093D12I3A8DDD58 IL Manufacturing
Open in API
Filings indexed 190 across all filing types
Latest filing 2026-04-28 Report Publication Anno…
Country GB United Kingdom
Listing IL AREC

About ARECOR THERAPEUTICS PLC

https://arecor.com/

Arecor Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing enhanced therapeutic medicines. The company utilizes its proprietary Arestat® technology platform, a formulation science designed to improve the properties of proteins and peptides, enabling superior drug product profiles. Arecor's business model involves two approaches: developing an internal portfolio of proprietary products and partnering with pharmaceutical and medtech companies to enhance their therapeutic offerings. The company's in-house development pipeline is primarily focused on advancing treatments for diabetes and other cardiometabolic diseases, including next-generation insulin candidates.

Recent filings

Filing Released Lang Actions
Posting of Annual Report and Notice of AGMm
Report Publication Announcement Classification · 95% confidence The document is a short RNS announcement (4,406 characters) stating that the company has published and posted its Annual Report and Accounts and the Notice of AGM, and provides links and details on how to access them. It does not contain the report itself but is an announcement of publication. Under the “menu vs meal” rule, this is a Report Publication Announcement.
2026-04-28 English
Final Results
Earnings Release Classification · 85% confidence The document is an RNS announcement of Arecor Therapeutics plc’s audited full year results for the 12 months ended 31 December 2025. It provides operational and financial highlights, CEO/Chair commentary, and details of a webcast, but does not contain the full set of financial statements as would appear in a complete Annual Report (10-K). This initial release of periodical results fits the definition of an Earnings Release (ER). FY 2025
2026-04-13 English
Notice of FY25 Results
Report Publication Announcement Classification · 92% confidence The document is a short RNS press release (4,478 characters) titled “Notice of FY25 Results” that simply announces the date on which the full year results for the period ending 31 December 2025 will be published and provides details for a webcast and subsequent presentation release. It contains no actual financial results or detailed report content and fits the pattern of a Report Publication Announcement notifying investors of when and how the full year report will be made available.
2026-03-30 English
Ligand Pharmaceuticals Milestone Payment
Capital/Financing Update Classification · 82% confidence The document is a short RNS announcement (RNS Number 1455Y) from Arecor Therapeutics plc confirming receipt of a $0.5 million commercial milestone payment under a previously announced royalty financing agreement with Ligand. This constitutes an update on a financing event (non-dilutive milestone payment) rather than a full report (e.g., interim report) or general regulatory notice. Thus it falls under “Capital/Financing Update.”
2026-03-26 English
Arecor to present at Oppenheimer conference
Regulatory Filings Classification · 95% confidence The document is a press release distributed via the RNS (Reach) service announcing that Arecor Therapeutics PLC will be presenting at upcoming healthcare conferences. It does not contain financial results, board changes, or regulatory filings, but rather serves as a corporate announcement regarding investor relations activities and event participation. As it does not fit into specific categories like 'Investor Presentation' (which would be the slides themselves) or 'Earnings Release', it falls under the general regulatory announcement category.
2026-03-09 English
2025 Business Update
Earnings Release Classification · 100% confidence The document is an 'Earnings Release' (ER) issued by Arecor Therapeutics plc. It provides a '2025 Business Update' including unaudited financial highlights (revenue, cash position) and operational progress for the 12 months ended 31 December 2025. It explicitly states that audited results will be issued later in April 2026, distinguishing this as an initial announcement of results rather than the full annual report. It follows the standard RNS (Regulatory News Service) format for earnings updates. FY 2025
2026-02-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.